What is the 13F Pro Quality Score for OFIX?

13F Pro ranks Orthofix Medical Inc. (OFIX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View OFIX's current score at https://13fpro.ai/research/OFIX (free sign-up required for the full ranking).

Where does 13F Pro source OFIX data?

All Orthofix Medical Inc. fundamentals and ownership data come directly from SEC EDGAR. Orthofix Medical Inc. files with the SEC under CIK 884624. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is OFIX in?

Orthofix Medical Inc. (OFIX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is OFIX research updated on 13F Pro?

OFIX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Orthofix Medical Inc.(OFIX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 884624 OFIX stock profile & AI dashboard →

13F Pro Quality Score

32.9/100

Rank #2,248 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

48.3/100

Profitability

21.5/100

Balance Sheet

14.9/100

Earnings Quality

30.0/100

Free Cash Flow

22.8/100

Institutional Flow

69.3/100

Revenue Scale

45.2/100

Dilution Risk

31.3/100

OFIX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Orthofix Medical Inc. (OFIX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OFIX at 32.9/100 on a 32-signal composite quality model, placing it at rank #2,248 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (14.9) and profitability (21.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 31.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Orthofix Medical Inc. reports quarterly revenue of $196.7M, net income of $-20.9M, an operating margin of -7.3%. Top institutional holders of OFIX by reported 13-F value include Engine Capital Management,, Juniper Investment Company,, Rubric Capital Management, based on the most recent SEC filings. OFIX trades on the Nasdaq exchange and files with the SEC under CIK 884624. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OFIX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Orthofix Medical Inc. directly from SEC EDGAR. Orthofix Medical Inc.'s 13F Pro composite quality score has ranged between 28 and 54 since 2021, currently 32.9 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.

Revenue

Q1 2026

$196.7M

Net Income

Q1 2026

$-20.9M

Free Cash Flow

Q1 2026

$-28.3M

Operating Margin

Q1 2026

-7.3%

D/E Ratio

Q1 2026

0.51

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+2.9% YoY

$822.3MFY 2025

FY22 $460.7MFY23 $746.6MFY24 $799.5MFY25 $822.3M

Net Income

+26.8% YoY

$-92.2MFY 2025

FY22 $-19.8MFY23 $-151.4MFY24 $-126.0MFY25 $-92.2M

Operating Income

+3.8% YoY

$-81.4MFY 2025

FY22 $-13.3MFY23 $-139.1MFY24 $-84.6MFY25 $-81.4M

EPS (Diluted)

+29.4% YoY

$-2.33FY 2025

FY22 $-0.98FY23 $-4.12FY24 $-3.30FY25 $-2.33

Total Assets

-4.8% YoY

$850.6MFY 2025

FY22 $458.6MFY23 $925.3MFY24 $893.3MFY25 $850.6M

Total Debt

+0.2% YoY

$157.4MFY 2025

FY22 —FY23 $95.6MFY24 $157.0MFY25 $157.4M

Op. Cash Flow

+29.3% YoY

$33.3MFY 2025

FY22 $-11.5MFY23 $-45.8MFY24 $25.8MFY25 $33.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$822.3M +2.9%	$799.5M +7.1%	$746.6M +62.1%	$460.7M -0.8%	$464.5M +14.2%	$406.6M
Net Income	$-92.2M +26.8%	$-126.0M +16.8%	$-151.4M -666.6%	$-19.8M +48.5%	$-38.4M -1624.8%	$2.5M
Operating Income	$-81.4M +3.8%	$-84.6M +39.2%	$-139.1M -948.5%	$-13.3M -59.6%	$-8.3M -32.7%	$-6.3M
EPS (Diluted)	$-2.33 +29.4%	$-3.30 +19.9%	$-4.12 -320.4%	$-0.98 +49.7%	$-1.95 -1600.0%	$0.13
Total Assets	$850.6M -4.8%	$893.3M -3.5%	$925.3M +101.8%	$458.6M -3.8%	$476.6M -9.4%	$525.9M
Total Debt	$157.4M +0.2%	$157.0M +64.2%	$95.6M	—	—	—
Operating Cash Flow	$33.3M +29.3%	$25.8M +156.4%	$-45.8M -296.5%	$-11.5M -162.5%	$18.5M -75.1%	$74.3M

AI Insight: OFIX Financial Trends

Operating performance improved through 2025 but Q1 2026 showed concerning deterioration with negative operating cash flow and 41% debt spike.

• Operating income improved from -$49M in Q1 2025 to $0M in Q4 2025 before declining to -$14M in Q1 2026.

• Net income narrowed from -$53M in Q1 2025 to -$2M in Q4 2025, showing steady loss reduction.

• Total debt jumped 41% from $157M in Q4 2025 to $221M in Q1 2026.

⚠ Operating cash flow turned negative to -$18M in Q1 2026 after positive $28M in Q4 2025.

⚠ Equity declined from $546M in Q2 2024 to $435M in Q1 2026, a 20% erosion.

AI Insight: OFIX Ratio Trends

OFIX profitability remains deeply negative with operating margin at -7.3% in Q1 2026 after briefly turning positive in Q4 2025.

• Operating margin improved from -25.2% in Q1 2025 to -7.3% in Q1 2026, with brief positive territory of 0.2% in Q4 2025.

• ROIC recovered from -31.8% in Q1 2025 to -8.8% in Q1 2026, showing significant but incomplete progress toward positive returns.

• Debt-to-equity ratio increased from 0.35 in Q4 2025 to 0.51 in Q1 2026, representing the highest leverage in the dataset.

⚠ Company remains unprofitable across all quarters with ROE ranging from -2.0% to -46.3%, indicating persistent operational challenges.

⚠ Sharp deterioration from Q4 2025 positive operating margin back to negative territory may signal unsustained improvement.

Get alerted when OFIX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Orthofix Medical Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of OFIX

Engine Capital Management, LP
$50.4M4,390,779 sh
Juniper Investment Company, LLC
$45.6M3,976,959 sh
Rubric Capital Management LP
$42.7M3,721,715 sh
PARADIGM CAPITAL MANAGEMENT INC/NY
$37.9M3,304,899 sh
BlackRock, Inc.
$36.8M3,207,789 sh
ARMISTICE CAPITAL, LLC
$31.0M2,700,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$19.0M1,655,449 sh
MILLENNIUM MANAGEMENT LLC
$12.2M1,066,900 sh
GEODE CAPITAL MANAGEMENT, LLC
$10.8M938,885 sh
STATE STREET CORP
$10.4M907,432 sh

Fund	Value	Shares
Engine Capital Management, LP	$50.4M	4,390,779
Juniper Investment Company, LLC	$45.6M	3,976,959
Rubric Capital Management LP	$42.7M	3,721,715
PARADIGM CAPITAL MANAGEMENT INC/NY	$37.9M	3,304,899
BlackRock, Inc.	$36.8M	3,207,789
ARMISTICE CAPITAL, LLC	$31.0M	2,700,000
VANGUARD CAPITAL MANAGEMENT LLC	$19.0M	1,655,449
MILLENNIUM MANAGEMENT LLC	$12.2M	1,066,900
GEODE CAPITAL MANAGEMENT, LLC	$10.8M	938,885
STATE STREET CORP	$10.4M	907,432

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put OFIX on your watchlist

Track score changes the day Orthofix Medical Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is OFIX a good stock to buy?

13F Pro's AI-powered analysis of Orthofix Medical Inc. (OFIX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OFIX are available on the OFIX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own OFIX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OFIX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Orthofix Medical Inc.'s investment landscape.